$AZN
Market Cap:
$AZN SEC Filings
| Filing | Filed On |
|---|---|
| DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS | 01 Dec 2023 |
| TOTAL VOTING RIGHTS | 01 Dec 2023 |
| DIRECTOR/PDMR SHAREHOLDING | 24 Nov 2023 |
| TRUQAP APPROVED IN US FOR HR+ BREAST CANCER | 17 Nov 2023 |
| UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI | 14 Nov 2023 |
| IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER | 09 Nov 2023 |
| DIRECTOR DECLARATION | 09 Nov 2023 |
| 9M AND Q3 2023 RESULTS | 09 Nov 2023 |
| AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA | 09 Nov 2023 |
| TOTAL VOTING RIGHTS | 01 Nov 2023 |
| ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS | 01 Nov 2023 |
| ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS | 03 Oct 2023 |
| TOTAL VOTING RIGHTS | 02 Oct 2023 |
| DATO-DXD IMPROVED PFS IN BREAST CANCER | 25 Sep 2023 |
| ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT | 20 Sep 2023 |
| ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC | 15 Sep 2023 |
| FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT | 11 Sep 2023 |
| UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD | 06 Sep 2023 |
| TOTAL VOTING RIGHTS | 01 Sep 2023 |
| TOTAL VOTING RIGHTS | 01 Aug 2023 |
